The current research results of combination treatment of AXL inhibitors and EGFR TKIs in NSCLC indicate that AXL is a new target for reversing drug resistance 35, 36, and AXL small molecule inhibitors are also under development and testing. The gene discussed is AXL; the disease is non-small cell lung carcinoma.